Sleep disturbance, inflammation and depression risk in cancer survivors

Brain, Behavior, and Immunity

Volumn 30, Issue SUPPL., 2013, Pages

  Irwin, Michael R ^a   Olmstead, Richard E ^a   Ganz, Patricia A ^b   Haque, Reina ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Kaiser Permanente Southern California ^*  (United States)

Author keywords

Cancer; Depression; Inflammation; Insomnia; Sleep disturbance

Indexed keywords

TAMOXIFEN;

BEHAVIOR DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVOR; CANCER THERAPY; CIRCADIAN RHYTHM; COMORBIDITY; DEPRESSION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

DEPRESSION; DEPRESSIVE DISORDER; HUMANS; INFLAMMATION; NEOPLASMS; QUALITY OF LIFE; RISK; SLEEP DISORDERS; SURVIVORS;

EID: 84875366065     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.05.002     Document Type: Review

References (125)

1. Alexopoulos G.S. Depression in the elderly. Lancet 2005, 365:1961-1970.
2. Althuis M.D., Fredman L., Langenberg P.W., Magaziner J. The relationship between insomnia and mortality among community-dwelling older women. J. Am. Geriatr. Soc. 1998, 46:1270-1273.
3. Andrews G., Issakidis C., Sanderson K., Corry J., Lapsley H. Utilising survey data to inform public policy: comparison of the cost-effectiveness of treatment of ten mental disorders. Br. J. Psychiatry 2004, 184:526-533.
4. Andrykowski M.A., Curran S.L., Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J. Behav. Med. 1998, 21:1-18.
5. Ayas N.T., White D.P., Manson J.E., Stampfer M.J., Speizer F.E., Malhotra A., Hu F.B. A prospective study of sleep duration and coronary heart disease in women. Arch. Intern. Med. 2003, 163:205-209.
6. Barefoot J.C., Brummett B.H., Helms M.J., Mark D.B., Siegler I.C., Williams R.B. Depressive symptoms and survival of patients with coronary artery disease. Psychosom. Med. 2000, 62:790-795.
7. Beekman A.T., Deeg D.J., Geerlings S.W., Schoevers R.A., Smit J.H., van Tilburg W. Emergence and persistence of late life depression: a 3-year follow-up of the Longitudinal Aging Study Amsterdam. J. Affect. Disord. 2001, 65:131-138.
8. Beekman A.T., Deeg D.J., Smit J.H., van Tilburg W. Predicting the course of depression in the older population: results from a community-based study in The Netherlands. J. Affect. Disord. 1995, 34:41-49.
9. Berger A.M., Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol. Nurs. Forum 1999, 26:1663-1671.
10. Berger A.M., Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study. Oncol. Nurs. Forum 2000, 27:1443-1448.
11. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddock C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol. Psychiatry 2009, 14:1095-1104.
12. Buysse D.J., Reynolds C.F., Hoch C.C., Houck P.R., Kupfer D.J., Mazumdar S., Frank E. Longitudinal effects of nortriptyline on EEG sleep and the likelihood of recurrence in elderly depressed patients. Neuropsychopharmacology 1996, 14:243-252.
13. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
14. Chisholm D., Sanderson K., Ayuso-Mateos J.L., Saxena S. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br. J. Psychiatry 2004, 184:393-403.
15. Cho H.J., Lavretsky H., Olmstead R., Levin M.J., Oxman M.N., Irwin M.R. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am. J. Psychiatry 2008, 165:1543-1550.
16. Cimprich B. Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs. 1999, 22:185-194. quiz 195.
17. Cole M.G., Dendukuri N. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am. J. Psychiatry 2003, 160:1147-1156.
18. Cole S.W. Chronic inflammation and breast cancer recurrence. J. Clin. Oncol. 2009, 27:3418-3419.
19. Coyne J.C., Schwenk T.L., Fechner-Bates S. Nondetection of depression by primary care physicians reconsidered. Gen. Hosp. Psychiatry 1995, 17:3-12.
20. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
21. Cytokines, Stress and Depression 1999, Kluwer Academic Publishers, New York. R. Dantzer, E.E. Wollman, R. Yirmiya (Eds.).
22. Davidson J.R., MacLean A.W., Brundage M.D., Schulze K. Sleep disturbance in cancer patients. Soc. Sci. Med. 2002, 54:1309-1321.
23. Denihan A., Kirby M., Bruce I., Cunningham C., Coakley D., Lawlor B.A. Three-year prognosis of depression in the community-dwelling elderly. Br. J. Psychiatry 2000, 176:453-457.
24. Dew M.A., Hoch C.C., Buysse D.J., Monk T.H., Begely A.E., Houck P.R., Hall M., Kupper D.J., Reynold C.F. Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. Psychosom. Med. 2003, 65:63-73.
25. Dew M.A., Reynolds C.F., Mulsant B., Frank E., Houck P.R., Mazumdar S., Begley A., Kupfer D.J. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. J. Affect. Disord. 2001, 65:155-166.
26. Dombrovski A.Y., Mulsant B.H., Houck P.R., Mazumdar S., Lenze E.J., Andreescu C., Cyranowski J.M., Reynolds C.F. Residual symptoms and recurrence during maintenance treatment of late-life depression. J. Affect. Disord. 2007, 103:77-82.
27. Duivis H.E., de Jonge P., Penninx B.W., Na B.Y., Cohen B.E., Whooley M.A. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am. J. Psychiatry 2011, 168:913-920.
28. Eisenberger N.I., Berkman E.T., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol. Psychiatry 2010, 68:748-754.
29. Eisenberger N.I., Inagaki T.K., Mashal N.M., Irwin M.R. Inflammation and social experience. an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav. Immun. 2010, 24:558-563.
30. Eisenberger N.I., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. Neuroimage 2009, 47:881-890.
31. Eisenberger N.I., Lieberman M.D. Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cogn. Sci. 2004, 8:294-300.
32. Ell K., Sanchez K., Vourlekis B., Lee P.J., Dwight-Johnson M., Lagomasino I., Muderspach L., Russell C. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer. J. Clin. Oncol. 2005, 23:3052-3060.
33. Engstrom C.A., Strohl R.A., Rose L., Lewandowski L., Stefanek M.E. Sleep alterations in cancer patients. Cancer Nurs. 1999, 22:143-148.
34. Evans D.L., Charney D.S., Lewis L., Golden R.N., Gorman J.M., Krishnan K.R., Nemeroff C.B., Bremner J.D., Carney R.M., Coyne J.C., Delong M.R., Frasure-Smith N., Glassman A.H., Gold P.W., Grant I., Gwyther L., Ironson G., Johnson R.L., Kanner A.M., Katon W.J., Kaufmann P.G., Keefe F.J., Ketter T., Laughren T.P., Leserman J., Lyketsos C.G., McDonald W.M., McEwen B.S., Miller A.H., Musselman D., O'Connor C., Petitto J.M., Pollock B.G., Robinson R.G., Roose S.P., Rowland J., Sheline Y., Sheps D.S., Simon G., Spiegel D., Stunkard A., Sunderland T., Tibbits P., Valvo W.J. Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry 2005, 58:175-189.
35. Fann J.R., Fan M.Y., Unutzer J. Improving primary care for older adults with cancer and depression. J. Gen. Intern. Med. 2009, 24(Suppl 2):S417-424.
36. Fann J.R., Thomas-Rich A.M., Katon W.J., Cowley D., Pepping M., McGregor B.A., Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. Gen. Hosp. Psychiatry 2008, 30:112-126.
37. Fiorentino L., Ancoli-Israel S. Insomnia and its treatment in women with breast cancer. Sleep Med. Rev. 2006, 10:419-429.
38. Flint A.J., Rifat S.L. Maintenance treatment for recurrent depression in late life. A four-year outcome study. Am. J. Geriatr. Psychiatry 2000, 8:112-116.
39. Ford D.E., Kamerow D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA 1989, 262:1479-1484.
40. Fortner B.V., Stepanski E.J., Wang S.C., Kasprowicz S., Durrence H.H. Sleep and quality of life in breast cancer patients. J. Pain Symptom Manage. 2002, 24:471-480.
41. Fredericks C.A., Drabant E.M., Edge M.D., Tillie J.M., Hallmayer J., Ramel W., Kuo J.R., Mackey S., Gross J.J., Dhabhar F.S. Healthy young women with serotonin transporter SS polymorphism show a pro-inflammatory bias under resting and stress conditions. Brain Behav. Immun. 2010, 24:350-357.
42. Gallo J.J., Bogner H.R., Morales K.H., Post E.P., Lin J.Y., Bruce M.L. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. Ann. Intern. Med. 2007, 146:689-698.
43. Gielissen M.F., Verhagen S., Witjes F., Bleijenberg G. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J. Clin. Oncol. 2006, 24:4882-4887.
44. Gimeno D., Kivimaki M., Brunner E.J., Elovainio M., De Vogli R., Steptoe A., Kumari M., Lowe G.D., Rumley A., Marmot M.G., Ferrie J.E. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol. Med. 2009, 39:413-423.
45. Goodwin J.S., Zhang D.D., Ostir G.V. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J. Am. Geriatr. Soc. 2004, 52:106-111.
46. Gotay C.C., Ransom S., Pagano I.S. Quality of life in survivors of multiple primary cancers compared with cancer survivor controls. Cancer 2007, 110:2101-2109.
47. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol. Psychiatry 2009, 66:407-414.
48. Himelhoch S., Weller W.E., Wu A.W., Anderson G.F., Cooper L.A. Chronic medical illness, depression, and use of acute medical services among Medicare beneficiaries. Med. Care 2004, 42:512-521.
49. Hogan D., Morrow J.D., Smith E.M., Opp M.R. Interleukin-6 alters sleep of rats. J. Neuroimmunol. 2003, 137:59-66.
50. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
51. Ickovics J.R., Hamburger M.E., Vlahov D., Schoenbaum E.E., Schuman P., Boland R.J., Moore J. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001, 285:1466-1474.
52. Imeri L., Opp M.R. How (and why) the immune system makes us sleep. Nat. Rev. Neurosci. 2009, 10:199-210.
53. Irwin M., Rinetti G., Redwine L., Motivala S., Dang J., Ehlers C. Nocturnal proinflammatory cytokine-associated sleep disturbances in abstinent African American alcoholics. Brain Behav. Immun. 2004, 18:349-360.
54. Irwin M.R., Carrillo C., Olmstead R. Sleep loss activates cellular markers of inflammation: sex differences. Brain Behav. Immun. 2010, 24:54-57.
55. Irwin M.R., Cole J.C., Nicassio P.M. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol. 2006, 25:3-14.
56. Irwin M.R., Cole S.W. Reciprocal regulation of the neural and innate immune systems. Nat. Rev. Immunol. 2011, 11:625-632.
57. Irwin M.R., Olmstead R. Mitigating cellular inflammation in older adults. Am. J. Geriatr. Psychiatry 2011, http://dx.doi.org/10.1097/JGP.0b013e3182330fd3.
58. Irwin M.R., Olmstead R., Valladares E.M., Breen E.C., Ehlers C.L. Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence. Biol. Psychiatry 2009, 66:191-195.
59. Irwin M.R., Wang M., Campomayor C.O., Collado-Hidalgo A., Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 2006, 166:1756-1762.
60. Irwin M.R., Wang M., Ribeiro D., Cho H.J., Olmstead R., Breen E.C., Martinez-Maza O., Cole S. Sleep loss activates cellular inflammatory signaling. Biol. Psychiatry 2008, 64:538-540.
61. Kangas M., Henry J.L., Bryant R.A. The course of psychological disorders in the 1st year after cancer diagnosis. J. Consult. Clin. Psychol. 2005, 73:763-768.
62. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
63. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62:617-627.
64. Kripke D.F., Garfinkel L., Wingard D.L., Klauber M.R., Marler M.R. Mortality associated with sleep duration and insomnia. Arch. Gen. Psychiatry 2002, 59:131-136.
65. Lavretsky H., Alstein L.L., Olmstead R.E., Ercoli L.M., Riparetti-Brown M., StCyr N., Irwin M.R. Complementary use of Tai Chi Chih augments escitalopram treatment of geriatric depression: a randomized controlled trial. Am. J. Geriatr. Psychiatry 2011, 19:839-850.
66. Lieberman M.D., Eisenberger N.I. Neuroscience. Pains and pleasures of social life. Science 2009, 323:890-891.
67. Liu L., Mills P.J., Rissling M., Fiorentino L., Natarajan L., Dimsdale J.E., Sadler G.R., Parker B.A., Ancoli-Israel S. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav. Immun 2012, http://dx.doi.org/10.1016/j.bbi.2012.02.001.
68. Liu L., Rissling M., Natarajan L., Fiorentino L., Mills P., Dimsdale J., Sadler G., Parker B., Ancoli-Israel S. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. Sleep 2012, 35:237-245.
69. Madhusudan S., Foster M., Muthuramalingam S.R., Braybrooke J.P., Wilner S., Kaur K., Han C., Hoare S., Balkwill F., Talbot D.C., Ganesan T.S., Harris A.L. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10:6528-6534.
70. Madhusudan S., Muthuramalingam S.R., Braybrooke J.P., Wilner S., Kaur K., Han C., Hoare S., Balkwill F., Ganesan T.S. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 2005, 23:5950-5959.
71. Mallon L., Broman J.E., Hetta J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population. J. Intern. Med. 2002, 251:207-216.
72. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
73. Massie M.J. Prevalence of depression in patients with cancer. J. Natl. Cancer Inst. Monogr., 2004, 32:57-71.
74. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3:e442.
75. Matthews K.A., Schott L.L., Bromberger J., Cyranowski J., Everson-Rose S.A., Sowers M.F. Associations between depressive symptoms and inflammatory/hemostatic markers in women during the menopausal transition. Psychosom. Med. 2007, 69:124-130.
76. Meier-Ewert H.K., Ridker P.M., Rifai N., Regan M.M., Price N.J., Dinges D.F., Mullington J.M. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J. Am. Coll. Cardiol. 2004, 43:678-683.
77. Miller A.H., Ancoli-Israel S., Bower J.E., Capuron L., Irwin M.R. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J. Clin. Oncol. 2008, 26:971-982.
78. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
79. Mills P.J., Ancoli-Israel S., Parker B., Natarajan L., Hong S., Jain S., Sadler G.R., von Kanel R. Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain Behav. Immun. 2008, 22:98-104.
80. Mills P.J., Parker B., Jones V., Adler K.A., Perez C.J., Johnson S., Cohen-Zion M., Marler M., Sadler G.R., Dimsdale J.E., Ancoli-Israel S. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin. Cancer Res. 2004, 10:4998-5003.
81. Mitchell A.J., Chan M., Bhatti H., Halton M., Grassi L., Johansen C., Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011, 12:160-174.
82. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., Guttridge D., Rhoades C., Shah M., Criswell T., Caligiuri M.A., Villalona-Calero M.A. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J. Clin. Oncol. 2006, 24:1852-1859.
83. Motivala S., Irwin M.R. Sleep and immunity: cytokine pathways linking sleep and health outcomes. Curr. Dir. Psychol. Sci. 2007, 16:21-25.
84. Mullington J., Korth C., Hermann D.M., Orth A., Galanos C., Holsboer F., Pollmächer T. Dose-dependent effects of endotoxin on human sleep. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278:R947-955.
85. Munoz R.F., Cuijpers P., Smit F., Barrera A.Z., Leykin Y. Prevention of major depression. Annu. Rev. Clin. Psychol. 2010, 6:181-212.
86. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon-alfa. NEJM 2001, 344:961-966.
87. Musselman D.L., Miller A.H., Porter M.R., Manatunga A.K., Gao F., Penna S., Pearce B.D., Landry J., Glover S., McDaniel J.S., Nemeroff C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 2001, 158:1252-1257.
88. Mykletun A., Bjerkeset O., Dewey M., Prince M., Overland S., Stewart R. Anxiety, depression, and cause-specific mortality: the HUNT study. Psychosom. Med. 2007, 69:323-331.
89. Newman A.B., Spiekerman C.F., Enright P., Lefkowitz D., Manolio T., Reynolds C.F., Robbins J. Daytime sleepiness predicts mortality and cardiovascular disease in older adults. J. Am. Geriatr. Soc. 2000, 48:115-123.
90. Nicassio P.M., Schuman C., Kim J., Cordova A., Weisman M.H. Psychosocial factors associated with complementary treatment use in fibromyalgia. J. Rheum. 1997, 24:2008-2013.
91. Nicklas B.J., Hsu F.C., Brinkley T.J., Church T., Goodpaster B.H., Kritchevsky S.B., Pahor M. Exercise training and plasma C-reactive protein and interleukin-6 in elderly people. J. Am. Geriatr. Soc. 2008, 56:2045-2052.
92. O'Connor M.F., Motivala S.J., Valladares E.M., Olmstead R., Irwin M.R. Sex differences in monocyte expression of IL-6: role of autonomic mechanisms. Am. J. Physiol. Reg. Integ. Comp. Physiol. 2007, 293:R145-151.
93. Office of Cancer Survivorship, 2009.
94. Onitilo A.A., Nietert P.J., Egede L.E. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen. Hosp. Psychiatry 2006, 28:396-402.
95. Pace T.W., Negi L.T., Adame D.D., Cole S.P., Sivilli T.I., Brown T.D., Issa M.J., Raison C.L. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology 2009, 34:87-98.
96. Palesh O.G., Roscoe J.A., Mustian K.M., Roth T., Savard J., Ancoli-Israel S., Heckler C., Purnell J.Q., Janelsins M.C., Morrow G.R. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer. J. Clin. Oncol. 2010, 28:292-298.
97. Pirl W.F., Greer J.A., Traeger L., Jackson V., Lennes I.T., Gallagher E.R., Perez-Cruz P., Heist R.S., Temel J.S. Depression and survival in metastatic non-small-cell lung cancer. J. Clin. Oncol. 2012, 30:1310-1315.
98. Polsky D., Doshi J.A., Marcus S., Oslin D., Rothbard A., Thomas N., Thompson C.L. Long-term risk for depressive symptoms after a medical diagnosis. Arch. Intern. Med. 2005, 165:1260-1266.
99. Raison C.L., Lowry C.A., Rook G.A. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch. Gen. Psychiatry 2010, 67:1211-1224.
100. Raison C.L., Miller A.H. Depression in cancer: new developments regarding diagnosis and treatment. Biol. Psychiatry 2003, 54:283-294.
101. Raison C.L., Rye D.B., Woolwine B.J., Vogt G.J., Bautista B.M., Spivey J.R., Miller A.H. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol. Psychiatry 2003, 68:942-949.
102. Redwine L., Dang J., Hall M., Irwin M. Disordered sleep, nocturnal cytokines, and immunity in alcoholics. Psychosom. Med. 2003, 65:75-85.
103. Reynolds C.F. Prevention of depressive disorders: a brave new world. Depress. Anxiety 2009, 26:1062-1065.
104. Rooney A.G., McNamara S., Mackinnon M., Fraser M., Rampling R., Carson A., Grant R. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. J. Clin. Oncol. 2011, 29:4307-4312.
105. Roscoe J.A., Morrow G.R., Hickok J.T., Mustian K.M., Griggs J.J., Matteson S.E., Bushunow P., Qazi R., Smith B. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res. Treat. 2005, 89:243-249.
106. Savard J., Morin C.M. Insomnia in the context of cancer: a review of a neglected problem. J. Clin. Oncol. 2001, 19:895-908.
107. Savard J., Simard S., Blanchet J., Ivers H., Morin C.M. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001, 24:583-590.
108. Schag C.A., Ganz P.A., Polinsky M.L., Fred C., Hirji K., Petersen L. Characteristics of women at risk for psychosocial distress in the year after breast cancer. J. Clin. Oncol. 1993, 11:783-793.
109. Schoevers R.A., Smit F., Deeg D.J., Cuijpers P., Dekker J., van Tilburg W., Beekman A.T. Prevention of late-life depression in primary care: do we know where to begin?. Am. J. Psychiatry 2006, 163:1611-1621.
110. Seruga B., Zhang H., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev Cancer 2008, 8:887-899.
111. Shearer W.T., Reuben J.M., Mullington J.M., Price N.J., Lee B.N., Smith E.O., Szuba M.P., Van Dongen H.P., Dinges D.F. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J. Allergy Clin. Immunol. 2001, 107:165-170.
112. Silberfarb P.M., Hauri P.J., Oxman T.E., Schnurr P. Assessment of sleep in patients with lung cancer and breast cancer. J. Clin. Oncol. 1993, 11:997-1004.
113. Soygur H., Palaoglu O., Akarsu E.S., Cankurtaran E.S., Ozalp E., Turhan L., Ayhan I.H. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1242-1247.
114. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol. Psychiatry 2003, 54:269-282.
115. Steel J.L., Geller D.A., Gamblin T.C., Olek M.C., Carr B.I. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J. Clin. Oncol. 2007, 25:2397-2405.
116. Stein B.D., Meili R., Klein D. Datapoints: general medical costs of recipients of behavioral health care. Psychiatr. Serv. 2006, 57:620.
117. Stein K.D., Jacobsen P.B., Hann D.M., Greenberg H., Lyman G. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J. Pain Symptom Manage. 2000, 19:436-445.
118. Stommel M., Given B.A., Given C.W. Depression and functional status as predictors of death among cancer patients. Cancer 2002, 94:2719-2727.
119. Su S., Zhao J., Bremner J.D., Miller A.H., Tang W., Bouzyk M., Snieder H., Novik O., Afzal N., Goldberg J., Vaccarino V. Serotonin transporter gene, depressive symptoms, and interleukin-6. Circ. Cardiovasc. Genet. 2009, 2:614-620.
120. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
121. Uher R., McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol. Psychiatry 2008, 13:131-146.
122. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Lotsikas A., Zachman K., Kales A., Prolo P., Wong M.L., Licinio J., Gold P.W., Hermida R.C., Mastorakos G., Chrousos G.P. Circadian interleukin-6 secretion and quantity and depth of sleep. J. Clin. Endocrin. Metab. 1999, 84:2603-2607.
123. Vos T., Haby M.M., Barendregt J.J., Kruijshaar M., Corry J., Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Arch. Gen. Psychiatry 2004, 61:1097-1103.
124. Wang X.S., Shi Q., Williams L.A., Mao L., Cleeland C.S., Komaki R.R., Mobley G.M., Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav. Immun. 2010, 24:968-974.
125. Zautra A.J., Davis M.C., Reich J.W., Nicassio P., Tennen H., Finan P., Kratz A., Parrish B., Irwin M.R. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J. Consult. Clin. Psychol. 2008, 76:408-421.